For years, the industry has attempted to solve the complex problem of underrepresentation in groups of people who are disproportionately burdened by some diseases. We also continue to seek the barriers. In this session, we will discuss some new ideas being piloted to solve complex issues of underrepresentation in trials and ways to build community relationships with promise, offer solutions for self-sustaining infrastructure, and consider how we may partner with other sponsors in a pre-competitive way.

AI is reshaping clinical research, but adoption without appropriate scrutiny can create as much risk as value. This sponsor-side session separates practical AI applications from vendor hype, exploring where AI can improve trial efficiency, oversight, and decision-making, and where it may introduce operational, quality, privacy, intellectual property, and regulatory risks. Attendees will examine the potential consequences of automation bias, inaccurate outputs, inadequate governance, and diminished human oversight, while gaining a practical framework for evaluating AI solutions based on measurable value, appropriate controls, and potential impact on trial execution.

Advancing a Phase 3 clinical program within a small biotech requires a fundamentally different operating model than that of large pharmaceutical organizations. This session explores practical and innovative approaches to maximizing limited resources, leveraging strategic partnerships, building agile teams, and prioritizing high-value activities. Attendees will learn how creative thinking, cross-functional collaboration, and disciplined decision-making can enable small biotechs to execute large, complex trials without compromising quality, timelines, or patient experience.